₹441.9
▲ +0.13 +0.03%
17 Jul 2026
NSE Listed
ASM 1Cohance Lifesciences Ltd. (COHANCE)
Volume: 3,99,035Avg Vol 1W: 3,82,868Avg Vol 1M: 6,05,57952W Range:₹266.7₹1,121.15
Key Ratios
Checked 15h agoMarket Cap₹15,406 Cr
Current Price₹441.9
Previous Close₹441.77
High / Low (52w)₹1,121.15 / ₹266.7
Volume3,99,035
Avg Vol (1W)3,82,868
Avg Vol (1M)6,05,579
Stock P/E108.7
Book Value₹90.95
Dividend Yield—
ROE12.5%
ROA—
Revenue (TTM)₹1,256 Cr
Revenue Growth—
Profit Margin—
Total Debt₹6 Cr
Shares Outstanding—
Face Value₹1
EPS (TTM)₹10.67
P/B12.75
Debt / Equity0.04
50 DMA₹436.88
200 DMA₹475.96
Day change+0.03%
SurveillanceASM 1 (as of 2026-07-11)
Price Chart
₹441.9▼ 59.72% · 1Y
2025-07-172026-07-16
20-day avg volume: 6.1L shares
Pros
- Company is almost debt-free.
Cons
- Revenue fell 17% YoY.
- Stock trades at a high P/E of 109.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹488 Cr | ₹604 Cr | ₹676 Cr | ₹840 Cr | ₹549 Cr | ₹556 Cr | ₹545 Cr | ₹619 Cr |
| EBITDA | ₹113 Cr | ₹184 Cr | ₹215 Cr | ₹187 Cr | ₹81 Cr | ₹93 Cr | ₹55 Cr | ₹46 Cr |
| Net Profit | ₹75 Cr | ₹138 Cr | ₹153 Cr | ₹120 Cr | ₹49 Cr | ₹74 Cr | ₹37 Cr | ₹20 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | ₹378 Cr | ₹852 Cr | ₹1,024 Cr | ₹1,413 Cr | ₹1,387 Cr | ₹1,113 Cr | ₹1,256 Cr |
| EBITDA | ₹161 Cr | ₹376 Cr | ₹423 Cr | ₹633 Cr | ₹565 Cr | ₹413 Cr | ₹356 Cr |
| Net Profit | ₹109 Cr | ₹317 Cr | ₹362 Cr | ₹454 Cr | ₹411 Cr | ₹300 Cr | ₹268 Cr |
| EPS | 8.59 | 12.45 | 14.23 | 17.83 | 16.16 | 11.8 | 10.45 |
Balance Sheet
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹783 Cr | ₹1,173 Cr | ₹1,474 Cr | ₹1,830 Cr | ₹1,966 Cr | ₹2,254 Cr | ₹3,032 Cr |
| Total Liabilities | ₹193 Cr | ₹328 Cr | ₹294 Cr | ₹302 Cr | ₹231 Cr | ₹203 Cr | ₹1,191 Cr |
| Equity | ₹590 Cr | ₹845 Cr | ₹1,181 Cr | ₹1,527 Cr | ₹1,735 Cr | ₹2,051 Cr | ₹1,841 Cr |
| Total Debt | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Operating | ₹83 Cr | ₹493 Cr | ₹492 Cr | ₹514 Cr | ₹603 Cr | ₹468 Cr | ₹372 Cr |
| Investing | ₹-65 Cr | ₹-413 Cr | ₹-311 Cr | ₹-136 Cr | ₹-195 Cr | ₹-362 Cr | ₹-255 Cr |
| Financing | ₹26 Cr | ₹7 Cr | ₹-76 Cr | ₹-156 Cr | ₹-242 Cr | ₹-14 Cr | ₹3 Cr |
| Free Cash Flow | ₹83 Cr | ₹493 Cr | ₹492 Cr | ₹514 Cr | ₹603 Cr | ₹468 Cr | ₹372 Cr |
Shareholding
Promoter 57.49% Institutions 27.38% Public 15.13%
Efficiency & Working Capital
ROCE5.5%
Interest Coverage25.5
Dividend Payout—
Debtor Days87 d
Inventory Days51 d
Payable Days24 d
Cash Conversion Cycle113 d
Working Capital Days137 d
Shareholding Details
As of 2026-03-31
Promoter57.5%
FII5.6%
DII21.8%
Institutions27.4%
Public15.1%
Promoter Pledge100%
No. of Shareholders85,230
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | May 2025 | May 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 60% | 50.1% | 50.1% | 50.1% | 50.1% | 50.1% | 66.4% | 66.4% | 66.4% | 57.5% | 57.5% | 57.5% |
| FIIs | 10.1% | 9.5% | 9.8% | 10.7% | 10.8% | 11% | 7.4% | 7.4% | 7.2% | 6.5% | 6% | 5.6% |
| DIIs | 15.9% | 17.2% | 17.4% | 16.9% | 16.7% | 16.6% | 11% | 11% | 11.4% | 20.8% | 21.6% | 21.8% |
| Public | 13.9% | 23.1% | 22.7% | 22.3% | 22.4% | 22.2% | 15.2% | 15.2% | 15% | 15.2% | 14.9% | 15.1% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 100% | 100% | 100% | 100% |
| No. of Shareholders | 70,052 | 68,932 | 65,777 | 69,337 | 84,210 | 86,325 | 88,658 | 88,658 | 80,910 | 75,284 | 81,877 | 85,230 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Berhyanda Limited | Shareholding of Promoter and Promoter Group | 33.3% | 12.75 Cr |
| Jusmiral Holdings Limited | Shareholding of Promoter and Promoter Group | 24.2% | 9.24 Cr |
| Dsp Nifty Smallcap 250 Etf | Public Shareholding | 4.8% | 1.82 Cr |
| Icici Prudential Value Fund | Public Shareholding | 4.5% | 1.72 Cr |
| Jasub Property Holdings Llp | Public Shareholding | 3.8% | 1.47 Cr |
| Hdfc Mutual Fund - Hdfc Bse 500 Etf | Public Shareholding | 3.1% | 1.20 Cr |
| Jasti Property And Equity Holdings Private Limited | Public Shareholding | 2.5% | 96,16,009 |
| Sbi Life Insurance Co. Ltd | Public Shareholding | 2% | 77,25,076 |
| Invesco India Contra Fund | Public Shareholding | 1.4% | 54,90,268 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Berhyanda Limited | 12.75 Cr | 100% | 2026-03-31 |
| Jusmiral Holdings Limited | 9.24 Cr | 100% | 2026-03-31 |
| Icici Prudential Value Fund | 0 | 0% | 2026-03-31 |
| Dsp Nifty Smallcap 250 Etf | 0 | 0% | 2026-03-31 |
| Hdfc Mutual Fund - Hdfc Bse 500 Etf | 0 | 0% | 2026-03-31 |
| Invesco India Contra Fund | 0 | 0% | 2026-03-31 |
| Sbi Life Insurance Co. Ltd | 0 | 0% | 2026-03-31 |
| Jasti Property And Equity Holdings Private Limited | 0 | 0% | 2026-03-31 |
| Jasub Property Holdings Llp | 0 | 0% | 2026-03-31 |
| Berhyanda Limited | 12.75 Cr | 100% | 2025-12-31 |
| Jusmiral Holdings Limited | 9.24 Cr | 100% | 2025-12-31 |
| Icici Prudential Equity & Debt Fund | 0 | 0% | 2025-12-31 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Vivek Sharma | Chairman & Exec. Director | 2025 |
| Vinod Padikkal | Non-Exec & Non-Independent Dir | 2025 |
| K G Ananthakrishnan | Independent Non Exe. Director | 2025 |
| Matangi Gowrishankar | Independent Non Exe. Director | 2025 |
| Vinod Rao | Independent Non Exe. Director | 2025 |
| U B Pravin Rao | Independent Non Exe. Director | 2025 |
| Jaishankar Krishnan | Independent Non Exe. Director | 2025 |
| Pankaj Patwari | Non Executive Director | 2025 |
| Shweta Jalan | Non Executive Director | 2025 |
| KUNDAN KUMAR JHA | CS / Compliance Officer / Legal Head | 2025 |
| Himanshu Agarwal | Whole Time Director & Chief Financial Officer | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Manufacturing of Bulk Drugs & Inter | ₹0 Cr | — |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| USA | ₹173 Cr | 16.2% |
| Europe | ₹748 Cr | 70% |
| India | ₹72 Cr | 6.7% |
| Others | ₹76 Cr | 7.1% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹1 | 40 | 25 | 25 |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 2 | 0 | 0 | 25 | 0 | 27 |
| 2025 | 0 | 0 | 0 | 7 | 0 | 7 |
| 2025 | 0 | 0 | 0 | 18 | 0 | 18 |
Insider / Designated-Person Trades
7 recent disclosure(s)
Jusmiral Holdings LimitedDisposal · 3,41,48,000
Dr. Venkata Naga Kali Vara Prasada Raju VetukuriDisposal · 6,00,000
Dr. Venkata Naga Kali Vara Prasada Raju VetukuriAcquisition · 7,13,259
Jusmiral Holdings LimitedAcquisition · 12,65,38,578
JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED in its capacity as sole Trustee of the Jasti Family TrustDisposal · 12,75,37,043
PADMAJA J.A.SDisposal · 28,000
Substantial Acquisitions (SAST)
18 disclosure(s)
Inter-se Transfer23/02/2026 · 77,00,000
Inter-se Transfer18/02/2026 · 70,00,000
Market18/02/2026 · 78,76,948
Release Of Encumbrances18/09/2025 · —
Market18/09/2025 · 3,41,48,000
Encumbrance Created09/05/2025 · —
Company Information
🌐 www.suvenpharm.com ↗
📍 8-2-334 SDE Serene Chambers, 3 Floor Avenue 7 Road No 5, Hyderabad, Telangana, 500034
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search